S&P Pharma Dose

Follow S&P Pharma Dose
Share on
Copy link to clipboard

Hosted by Arthur Wong, Ji Liu, and other editors and analysts, the S&P Pharma Dose podcast from S&P Global Ratings discusses all things pharma from a credit perspective.

S&P Global Ratings


    • Sep 21, 2020 LATEST EPISODE
    • infrequent NEW EPISODES
    • 11m AVG DURATION
    • 35 EPISODES


    Search for episodes from S&P Pharma Dose with a specific topic:

    Latest episodes from S&P Pharma Dose

    What Bausch RemainCo's Credit Quality Post-Spinoff Could Look Like

    Play Episode Listen Later Sep 21, 2020 7:06


    In this episode, Ji Liu, primary analyst for Bausch Health, discusses a number of investor questions after Bausch announced its intention to spin off its eye health business unit, specifically regarding its capital structure, key business strengths, key business weaknesses, and other concerns.

    Regeneron Pharmaceuticals: Steady Growth vs. Heavy Product Concentration

    Play Episode Listen Later Aug 5, 2020 8:02


    S&P Global Ratings' senior pharma analyst, Ji Liu, discusses the puts and takes for our new Regeneron Pharmaceuticals ratings.

    Episode 34: More Color on PPD's Rating After IPO

    Play Episode Listen Later Feb 11, 2020 6:48


    In this episode of S&P Pharma Dose, senior healthcare analyst Ji Liu discusses his view on Pharmaceutical Product Development LLC (PPD) after its recent IPO on Feb. 5, 2020.

    Episode 33: Pharmacy Benefit Manager Industry In 2020: Less Regulatory Overhang, Expect More Consolidations

    Play Episode Listen Later Jan 21, 2020 10:25


    In this episode of S&P Pharma Dose, Ji Liu, Deep Banerjee and Andy Sookram discuss the annual PBM outlook report along with their view on high-profile issuers UnitedHealth, Cigna, CVS and Rite Aid.

    Episode 32: Pfizer Finds Home For Upjohn, Though Lessened Diversity Results In Lower Rating

    Play Episode Listen Later Aug 1, 2019 8:45


    The S&P Pharma Guy, Arthur Wong, shares S&P Global's thoughts on Pfizer Inc.'s announcement it was spinning off Upjohn, home to legacy products Lipitor, Viagra, and Lyrica. Pfizer remains a pharma giant and leading player in the industry. However, the lessened diversity will result in a lower rating.

    Episode 31: Thoughts On Pharma's Washington Grilling

    Play Episode Listen Later Mar 7, 2019 12:08


    S&P Global's pharmaceutical themed podcast show returns with some quick thoughts on the pharma industry's testimony at a congressional hearing on Capitol Hill. A comprehensive list of challenges/criticisms of the industry, but where were the suggested solutions? Noise level on pharma pricing is only going to increase as we near presidential election.

    Episode 30: Rebates And Pharma Supply Chain

    Play Episode Listen Later Aug 3, 2018 10:06


    Healthcare analysts Tulip Lim and Ji Liu drop in on the S&P Pharma Guy, Arthur Wong, to talk how HHS's proposal to ban rebating from the Medicare market. What's the impact on the ratings of the pharma supply chain players?

    Episode 29: Just When You Thought It Was Safe to Go Back In the Water - Amazon Buys PillPack

    Play Episode Listen Later Jul 11, 2018 17:26


    Managing Director, Bob Schulz from S&P Global's retail team and Director, Tulip Lim, of the healthcare team drop in on the show to share thoughts on Amazon's recent no-longer-a-rumor move into the pharmacy space. What does it mean for the pharmaceutical supply chain? How concerned should we be from a ratings standpoint for the pharmacy chains and pharma wholesalers?

    Episode 28: President Trump's American Patient First Speech - Placebo?

    Play Episode Listen Later May 18, 2018 10:38


    The S&P Pharma Guy, Arthur Wong, shares S&P Global's initial thoughts on President Trump's recent speech on lowering drug prices. The speech questioned the validity of drug rebates and criticized foreign countries for paying too little for drugs, but stopped short of limiting proposing pharma list price increases or enabling Medicare to negotiate directly for pricing. Limited credit impact?

    Episode 27: Bezos, Buffett, and Dimon - Welcome to the Healthcare Party

    Play Episode Listen Later Feb 5, 2018 13:56


    A surprise announcement by Amazon.com Inc., Berkshire Hathaway Inc., and JPMorgan Chase & Co. that they are jointly forming a new company to tackle health costs for their employees has caused quite a stir. S&P pharma analyst, Arthur Wong, shares his quick thoughts and takeaways as to what it may mean for pharma.

    Episode 26: Generic Drug Pricing - When Does the Pain Stop?

    Play Episode Listen Later Feb 2, 2018 17:38


    The S&P Pharma Guy, Arthur Wong, shares why generic drug pricing in the U.S., which has been under increasing pressure, should begin to stabilize in 2018. However, the U.S. generic drug environment will likely remain challenging over the near term and S&P harbors longer-term concerns on the industry.

    Episode 25: Four Things We Are Watching For On Teva

    Play Episode Listen Later Dec 7, 2017 18:03


    The S&P Pharma Guy, Arthur Wong details four things S&P is watching for on Teva over the next three quarters that would help determine whether the ratings stay investment grade.

    Episode 24: Et Tu Amazon? Amazon and Impact on Pharma Pricing

    Play Episode Listen Later Nov 15, 2017 9:16


    S&P Global Ratings analyst Arthur Wong takes an early look as to what a possible entry of Amazon.com Inc. into the pharma ecosystem may mean to drug pricing for generic and branded pharma. Warning: More questions than answers at this point.

    Episode 23: CVS Health Possibly Seeks to Buy Aetna - Surprised? You Shouldn't Be

    Play Episode Listen Later Nov 3, 2017 7:56


    S&P Global Ratings analyst Arthur Wong shares why a potential CVS Health/Aetna is not that all surprising, and that it will mean more pricing pressure on the pharmaceutical industry as well as drive further consolidation in the pharmaceutical channel and amongst pharmaceutical companies.

    Episode 22: Reflections - Mylan NV Earnings 2Q17

    Play Episode Listen Later Sep 6, 2017 11:27


    Guest analyst, Kim Logan, drops in to share her reflections on generic giant Mylan NV's second quarter performance and shares her thoughts on the company maintaining investment grade ratings.

    Episode 21: Endo Intl Downgrade to 'B' - Litigation, Generics, and Opioids

    Play Episode Listen Later Aug 17, 2017 13:48


    S&P Global Ratings analyst Arthur Wong discusses the recent downgrade of Endo International, which took another significant charge for its mesh litigation settlement, while dealing with ongoing pressures in the generic and opioid markets.

    Episode 20: Rite Aid Corp. - What's Next For the Company?

    Play Episode Listen Later Aug 16, 2017 8:31


    S&P Global Ratings retail analyst Andy Sookram swings by the show to discuss the ratings and prospects of major U.S. pharmacy player, Rite Aid, now that its merger with rival Walgreens Boots Alliance Inc. has been canceled, and is instead selling roughly half its stores to Walgreens.

    Episode 19: Reflections - Eli Lilly Earnings 2Q17

    Play Episode Listen Later Jul 26, 2017 10:32


    S&P Global Ratings credit analyst Arthur Wong shares his thoughts on Eli Lilly's recent earnings call, including thoughts on top drug prospect, the rheumatoid arthritis treatment, baricitinib, continued sales and margin growth, pipeline challenges, and the potential for M&A, all in the context of the ratings.

    Episode 17: Pharma Outlook in 7 Minutes

    Play Episode Listen Later Jun 15, 2017 9:08


    S&P Global Ratings credit analyst Arthur Wong attempts to share S&P's current thoughts on the ratings outlook for pharmaceuticals in seven minutes or less, given looming U.S. corporate tax reform, continued industry M&A, and challenges faced by the generics and specialty pharma subsectors.

    Episode 16: Four Takeaways - Amgen Inc.

    Play Episode Listen Later Jun 15, 2017 12:20


    S&P Global Ratings credit analyst Arthur Wong discusses the ratings and outlook on Amgen Inc., its challenge in replacing the declining sales of stalwart products such as Epogen/Aranesp, Neupogen/Neulasta, and Enbrel, and its capacity for debt financed acquisitions/share repurchases.

    Episode 15: Pharma Chat - CRO Consolidation

    Play Episode Listen Later Jun 15, 2017 17:02


    S&P Global Ratings credit analysts Matt Todd and Arthur Wong chat about various recent topics in the industry, including consolidation in the contract research organization space and the potential return of speculative inventory buying.

    Episode 14: PBMs Still Have a Role? Focus on Express Scripts

    Play Episode Listen Later Apr 5, 2017 15:30


    S&P Global Ratings credit analyst Shannan Murphy drops in on the show to discuss the role of pharmacy benefit managers (PBMs) in this changing health care market, with a focus on a major independent PBM, Express Scripts Holding Co.

    Episode 13: Four Takeaways - Merck & Co.

    Play Episode Listen Later Apr 5, 2017 9:28


    S&P Global Ratings credit analyst Arthur Wong discusses the ratings and outlook on Merck & Co. Inc., prospects of Keytruda, and what capacity the company has for acquisitions at the current ratings.

    Episode 12: Pharma Chat - It's All in the Transparency

    Play Episode Listen Later Feb 2, 2017 9:12


    Analysts Arthur Wong and Adam Dibe discuss pharma trying to improve their public image, pharma pricing and transparency, Merck's disclosing their gross and net pricing, and Johnson & Johnson's acquisition of Actelion.

    Episode 11: Four Takeaways - Eli Lilly

    Play Episode Listen Later Jan 13, 2017 10:21


    Analyst Arthur Wong discusses the ratings and outlook on Eli Lilly, in the wake of the company's upbeat earnings guidance despite the recent loss of its high profile drug prospect, the Alzheimer's treatment, solanezumab.

    Episode 10: U.S. Tax Reform - Positive But Some Near Term Concerns For Pharma Ratings

    Play Episode Listen Later Dec 15, 2016 21:33


    Analyst Arthur Wong shares S&P's thoughts on potential U.S. corporate tax reform, and discuss that while it could be a long term positive for the pharmaceutical industry, there are some concerns in the period immediately following implementation, mainly around what companies would do with all that cash.

    Episode 9: Pharma and Trump

    Play Episode Listen Later Nov 28, 2016 9:32


    Analyst Arthur Wong explores the potential mixed credit implications the Donald Trump presidential election win may hold for the pharmaceutical industry.

    Episode 8: Generic Drug Pricing

    Play Episode Listen Later Nov 28, 2016 9:59


    Analysts Tulip Lim and Kim Logan join the show to discuss their thoughts on pricing in the generic drug space.

    Episode 7: Pharma Chat - Recent Topics

    Play Episode Listen Later Jul 22, 2016 11:53


    Healthcare analysts Arthur Wong and Adam Dibe chat about some recent pharma developments – Amgen's biosimilar on Humira, Big Pharma's interest in biopharmaceutical company, Medivation, Inc., and an investor question on specialty pharma company Endo International PLC.

    Episode 6: S&P's Positive Ratings Outlook for CROs - What is driving it?

    Play Episode Listen Later Jul 12, 2016 13:00


    In this episode, healthcare analyst Matt Todd chats about what is driving the recent positive ratings actions in the contract research organization (CRO) space.

    Episode 5: Brexit & Pharma - No Rating Changes, But Negative Implications

    Play Episode Listen Later Jul 12, 2016 10:04


    Healthcare analysts Arthur Wong and Adam Dibe discuss their quick thoughts on Brexit and what it means for U.S. rated pharma companies. No rating changes at this time, but some concerns on what Brexit may mean for product approval times and research funding.

    Episode 4: What's Behind The Ratings On Amgen

    Play Episode Listen Later May 5, 2016 7:09


    In this episode, healthcare analysts Arthur Wong and Adam Dibe address questions regarding the prospects for Amgen's core portfolio, its drug pipeline, the competition, and its increasing capacity for acquisitions.

    Episode 2: What Lies Ahead For Teva

    Play Episode Listen Later Feb 25, 2016 6:22


    In this episode, healthcare analyst Arthur Wong discusses our expectations for the ratings on generic drug giant Teva, which is seeking to close its $40.5 billion acquisition of Allergan's generic business. Mr. Wong also fields investors' questions concerning the prospects for Teva's business side and its stance on acquisitions.

    Episode 1: Our Rating Action On Gilead

    Play Episode Listen Later Feb 25, 2016 8:17


    In this episode, healthcare analysts Arthur Wong and Adam Dibe discuss the rationale behind our recent rating action on biopharmaceutical company Gilead and field investors' questions concerning the company, including growth expectations and its capacity for acquisitions.

    Episode 3: How Company Healthcare Exchanges Could Affect The Industry

    Play Episode Listen Later Feb 25, 2016 8:04


    In this episode, healthcare analyst Arthur Wong shares his thoughts on the potential rise of company healthcare exchanges and what impact these entities may have on the pharmaceutical industry and pharmaceutical company ratings.

    Claim S&P Pharma Dose

    In order to claim this podcast we'll send an email to with a verification link. Simply click the link and you will be able to edit tags, request a refresh, and other features to take control of your podcast page!

    Claim Cancel